Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 11, Number 6—June 2005
Perspective

Antimicrobial Resistance Determinants and Future Control

Stephan Harbarth*Comments to Author  and Matthew H. Samore†
Author affiliations: *University of Geneva Hospitals, Geneva, Switzerland; †VA Salt Lake City Health Care System, Salt Lake City, Utah, USA

Main Article

Table 3

Proportions of appropriate perioperative antimicrobial drug prophylaxis in Belgian hospitals after change in the reimbursement system*

1986 (%) 1999 (%)
Correct timing 53 70
Correct indication 92 97
Duration >48 h 50 8
Choice of agent
First-generation cephalosporin 28 66
Second-generation cephalosporin 17 29

*Source: Goossens et al (34).

Main Article

References
  1. Livermore  D. Can better prescribing turn the tide of resistance? Nat Rev Microbiol. 2004;2:73–8. DOIPubMedGoogle Scholar
  2. Weber  JT, Courvalin  P. An emptying quiver: antimicrobial drugs and resistance. Emerg Infect Dis. 2005;11:791–3. DOIPubMedGoogle Scholar
  3. Andersson  DI, Levin  BR. The biological cost of antibiotic resistance. Curr Opin Microbiol. 1999;2:489–93. DOIPubMedGoogle Scholar
  4. Harbarth  S, Albrich  W, Goldmann  DA, Huebner  J. Control of multiply resistant cocci: do international comparisons help? Lancet Infect Dis. 2001;1:251–61. DOIPubMedGoogle Scholar
  5. Nuermberger  EL, Bishai  WR. Antibiotic resistance in Streptococcus pneumoniae: what does the future hold? Clin Infect Dis. 2004;38(Suppl 4):S363–71. DOIPubMedGoogle Scholar
  6. Fischer  JE, Harbarth  S, Agthe  AG, Benn  A, Ringer  SA, Goldmann  DA, Quantifying uncertainty: physicians' estimates of infection in critically ill neonates and children. Clin Infect Dis. 2004;38:1383–90. DOIPubMedGoogle Scholar
  7. Christ-Crain  M, Jaccard-Stolz  D, Bingisser  R, Gencay  MM, Huber  PR, Tamm  M, Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet. 2004;363:600–7. DOIPubMedGoogle Scholar
  8. Gibot  S, Cravoisy  A, Levy  B, Bene  MC, Faure  G, Bollaert  PE. Soluble triggering receptor expressed on myeloid cells and the diagnosis of pneumonia. N Engl J Med. 2004;350:451–8. DOIPubMedGoogle Scholar
  9. Dunne  WM Jr, Pinckard  JK, Hooper  LV. Clinical microbiology in the year 2025. J Clin Microbiol. 2002;40:3889–93. DOIPubMedGoogle Scholar
  10. Raoult  D, Fournier  PE, Drancourt  M. What does the future hold for clinical microbiology? Nat Rev Microbiol. 2004;2:151–9. DOIPubMedGoogle Scholar
  11. Chastre  J, Wolff  M, Fagon  JY, Chevret  S, Thomas  F, Wermert  D, Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA. 2003;290:2588–98. DOIPubMedGoogle Scholar
  12. Micek  ST, Ward  S, Fraser  VJ, Kollef  MH. A randomized controlled trial of an antibiotic discontinuation policy for clinically suspected ventilator-associated pneumonia. Chest. 2004;125:1791–9. DOIPubMedGoogle Scholar
  13. Molstad  S, Lundborg  CS, Karlsson  AK, Cars  O. Antibiotic prescription rates vary markedly between 13 European countries. Scand J Infect Dis. 2002;34:366–71. DOIPubMedGoogle Scholar
  14. Patrick  DM, Marra  F, Hutchinson  J, Monnet  DL, Ng  H, Bowie  WR. Per capita antibiotic consumption: how does a North American jurisdiction compare with Europe? Clin Infect Dis. 2004;39:11–7. DOIPubMedGoogle Scholar
  15. Projan  SJ, Shlaes  DM. Antibacterial drug discovery: is it all downhill from here? Clin Microbiol Infect. 2004;10(Suppl 4):18–22. DOIPubMedGoogle Scholar
  16. Ganestam  F, Lundborg  CS, Grabowska  K, Cars  O, Linde  A. Weekly antibiotic prescribing and influenza activity in Sweden: a study throughout 5 influenza seasons. Scand J Infect Dis. 2003;35:836–42. DOIPubMedGoogle Scholar
  17. Fleming  DM, Ross  AM, Cross  KW, Kendall  H. The reducing incidence of respiratory tract infection and its relation to antibiotic prescribing. Br J Gen Pract. 2003;53:778–83.PubMedGoogle Scholar
  18. Zanetti  G, Blanc  DS, Federli  I, Berger  MM, Chiolero  R, Petignat  C, Acinetobacter baumannii epidemic in a burn unit: usefulness of improved culture medium to assess environmental contamination. In: Infectious Diseases Society of America Annual Meeting; Boston, 2004; Abstract 219.
  19. Harbarth  S, Albrich  W, Brun-Buisson  C. Outpatient antibiotic use and prevalence of antibiotic-resistant pneumococci in France and Germany: a sociocultural perspective. Emerg Infect Dis. 2002;8:1460–7.PubMedGoogle Scholar
  20. Bauraind  I, Lopez-Lozano  JM, Beyaert  A, Marchal  JL, Seys  B, Yane  F, Association between antibiotic sales and public campaigns for their appropriate use. JAMA. 2004;292:2468–70. DOIPubMedGoogle Scholar
  21. Finch  RG, Metlay  JP, Davey  PG, Baker  LJ. Educational interventions to improve antibiotic use in the community: report from the International Forum on Antibiotic Resistance (IFAR) colloquium, 2002. Lancet Infect Dis. 2004;4:44–53. DOIPubMedGoogle Scholar
  22. Oteo  J, Lazaro  E, de Abajo  FJ, Baquero  F, Campos  J. Trends in antimicrobial resistance in 1,968 invasive Streptococcus pneumoniae strains isolated in Spanish hospitals (2001 to 2003): decreasing penicillin resistance in children's isolates. J Clin Microbiol. 2004;42:5571–7. DOIPubMedGoogle Scholar
  23. Waldvogel  FA. Infectious diseases in the 21st century: old challenges and new opportunities. Int J Infect Dis. 2004;8:5–12. DOIPubMedGoogle Scholar
  24. Whitney  CG, Klugman  KP. Vaccines as tools against resistance: the example of pneumococcal conjugate vaccine. Semin Pediatr Infect Dis. 2004;15:86–93. DOIPubMedGoogle Scholar
  25. Reinert  RR. Pneumococcal conjugate vaccines – a European perspective. Int J Med Microbiol. 2004;294:277–94. DOIPubMedGoogle Scholar
  26. Tiemersma  EW, Bronzwaer  SL, Lyytikainen  O, Degener  JE, Schrijnemakers  P, Bruinsma  N, Methicillin-resistant Staphylococcus aureus in Europe, 1999–2002. Emerg Infect Dis. 2004;10:1627–34.PubMedGoogle Scholar
  27. Pittet  D, Hugonnet  S, Harbarth  S, Mourouga  P, Sauvan  V, Touveneau  S, Effectiveness of a hospital-wide programme to improve compliance with hand hygiene. Lancet. 2000;356:1307–12. DOIPubMedGoogle Scholar
  28. Tomic  V, Svetina Sorli  P, Trinkaus  D, Sorli  J, Widmer  AF, Trampuz  A. Comprehensive strategy to prevent nosocomial spread of methicillin-resistant Staphylococcus aureus in a highly endemic setting. Arch Intern Med. 2004;164:2038–43. DOIPubMedGoogle Scholar
  29. Cooper  BS, Medley  GF, Stone  SP, Kibbler  CC, Cookson  BD, Roberts  JA, Methicillin-resistant Staphylococcus aureus in hospitals and the community: stealth dynamics and control catastrophes. Proc Natl Acad Sci U S A. 2004;101:10223–8. DOIPubMedGoogle Scholar
  30. Bell  DM. Public health interventions and SARS spread, 2003. Emerg Infect Dis. 2004;10:1900–6.PubMedGoogle Scholar
  31. Carbon  C, Bax  RP. Regulating the use of antibiotics in the community. BMJ. 1998;317:663–5. DOIPubMedGoogle Scholar
  32. Bavestrello  L, Cabello  A, Casanova  D. Impact of regulatory measures in the trends of community consumption of antibiotics in Chile. Rev Med Chil. 2002;130:1265–72. DOIPubMedGoogle Scholar
  33. Harbarth  S, Samore  MH, Lichtenberg  D, Carmeli  Y. Prolonged antibiotic prophylaxis after cardiovascular surgery and its effect on surgical site infections and antimicrobial resistance. Circulation. 2000;101:2916–21.PubMedGoogle Scholar
  34. Goossens  H, Peetermans  W, Sion  JP, Bossens  M. Evidence-based perioperative antibiotic prophylaxis policy in Belgian hospitals after a change in the reimbursement system. Ned Tijdschr Geneeskd. 2001;145:1773–7.PubMedGoogle Scholar
  35. Harbarth  S, Oberlander  C. Do health care regulation and physician-industry interaction influence antibiotic resistance rates? The example of antimicrobial prescribing and dispensing in Japan. International Conference on Improving Use of Medicines. Chang Mai, Thailand: World Health Organization; 2004.
  36. Park  S, Soumerai  SB, Adams  AS, Finkelstein  JA, Jang  S, Ross-Degnan  D. Decreased inappropriate antibiotic use following a Korean national policy to prohibit medication dispensing by physicians. Health Policy Plan. 2005. In press. DOIPubMedGoogle Scholar
  37. Bruinsma  N, Kristinsson  KG, Bronzwaer  S, Schrijnemakers  P, Degener  J, Tiemersma  E, Trends of penicillin and erythromycin resistance among invasive Streptococcus pneumoniae in Europe. J Antimicrob Chemother. 2004;54:1045–50. DOIPubMedGoogle Scholar
  38. Reingold  AL. Infectious disease epidemiology in the 21st century: will it be eradicated or will it reemerge? Epidemiol Rev. 2000;22:57–63.PubMedGoogle Scholar
  39. Chabbert  YA. Aspects de la résistance des germes aux antibiotiques. Presse Med. 1952;79:1681–6.
  40. Cohen  ML. Epidemiology of drug resistance: implications for a post-antimicrobial era. Science. 1992;257:1050–5. DOIPubMedGoogle Scholar
  41. Chambers  HF. The changing epidemiology of Staphylococcus aureus. Emerg Infect Dis. 2001;7:178–82. DOIPubMedGoogle Scholar

Main Article

Page created: April 24, 2012
Page updated: April 24, 2012
Page reviewed: April 24, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external